BE
MCID: BRR014
MIFTS: 71

Barrett Esophagus (BE)

Categories: Cancer diseases, Gastrointestinal diseases, Genetic diseases, Liver diseases, Rare diseases

Aliases & Classifications for Barrett Esophagus

MalaCards integrated aliases for Barrett Esophagus:

Name: Barrett Esophagus 58 12 54 76 38 30 56 45 41 74
Barrett's Esophagus 12 54 15 17
Barrett Esophagus/esophageal Adenocarcinoma 58 13 6
Barrett's Ulcer of Esophagus 12 74
Esophageal Adenocarcinoma 60 17
Ulcerative Esophagitis 12 74
Barrett Metaplasia 58 76
Barrett Syndrome 77 54
Chronic Peptic Ulcer and Esophagitis Syndrome 54
Barrett's Esophagus with Esophagitis 12
Adenocarcinoma of the Esophagus 60
Adenocarcinoma of Esophagus 74
Peptic Ulcer of Esophagus 74
Esophagitis-Peptic Ulcer 54
Columnar-Like Esophagus 54
Barrett's Oesophagus 12
Barretts Syndrome 12
Barrett Ulcer 54
Be 76

Characteristics:

Orphanet epidemiological data:

60
adenocarcinoma of the esophagus
Inheritance: Not applicable; Prevalence: 1-9/100000 (Europe),1-9/1000000 (Worldwide); Age of onset: Adult; Age of death: adult;

HPO:

33
barrett esophagus:
Inheritance somatic mutation


Classifications:



External Ids:

Disease Ontology 12 DOID:9206
OMIM 58 614266
KEGG 38 H01901
ICD9CM 36 530.85
MeSH 45 D001471
NCIt 51 C2891
SNOMED-CT 69 76355008
ICD10 via Orphanet 35 C15.2 C15.5
UMLS via Orphanet 75 C0279628
Orphanet 60 ORPHA99976

Summaries for Barrett Esophagus

NIH Rare Diseases : 54 Barrett esophagus is a condition in which the lining of the esophagus (the tube that carries food from the throat to the stomach) is replaced by tissue that is similar to the lining of the intestines. Although this change does not cause any specific signs or symptoms, it is typically diagnosed in people who have long-term gastroesophageal reflux disease (GERD). The exact underlying cause of Barrett esophagus is not known; however, it generally occurs sporadically in people with no family history of the condition. Treatment varies by the severity of the condition and generally includes medications and life style modifications to ease the symptoms of GERD. Endoscopic or surgical treatments may be recommended in people with severe cases.

MalaCards based summary : Barrett Esophagus, also known as barrett's esophagus, is related to esophageal cancer and mesothelioma, malignant. An important gene associated with Barrett Esophagus is CTHRC1 (Collagen Triple Helix Repeat Containing 1), and among its related pathways/superpathways are Pathways in cancer and MicroRNAs in cancer. The drugs Abraxane and Abstral have been mentioned in the context of this disorder. Affiliated tissues include lung, breast and testes, and related phenotypes are obesity and gastroesophageal reflux

OMIM : 58 Barrett esophagus, or Barrett metaplasia, describes the phenotypic change of normal esophageal squamous epithelium to a columnar and intestinal-type epithelium. This metaplastic change is important because patients with Barrett esophagus have an increased risk of esophageal adenocarcinoma. The main cause of Barrett metaplasia is gastroesophageal reflux (GER; 109350). The retrograde movement of acid and bile salts from the stomach into the esophagus in this disease causes prolonged injury to the esophageal epithelium and induces chronic esophagitis, which in turn is believed to trigger the pathologic changes (summary by Wong et al., 2005). (614266)

UniProtKB/Swiss-Prot : 76 Barrett esophagus: A condition characterized by a metaplastic change in which normal esophageal squamous epithelium is replaced by a columnar and intestinal-type epithelium. Patients with Barrett esophagus have an increased risk of esophageal adenocarcinoma. The main cause of Barrett esophagus is gastroesophageal reflux. The retrograde movement of acid and bile salts from the stomach into the esophagus causes prolonged injury to the esophageal epithelium and induces chronic esophagitis, which in turn is believed to trigger the pathologic changes.

Wikipedia : 77 Barrett''s esophagus is a condition in which there is an abnormal (metaplastic) change in the mucosal... more...

Related Diseases for Barrett Esophagus

Diseases related to Barrett Esophagus via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 5865)
# Related Disease Score Top Affiliating Genes
1 esophageal cancer 32.7 CCND1 CDKN2A CDX2 GSTP1 PTGS2 TP53
2 mesothelioma, malignant 31.8 CDKN2A KRT20 KRT7
3 adenocarcinoma 31.8 ASCC1 CCND1 CDKN2A CTHRC1 PTGS2 TP53
4 small intestine adenocarcinoma 31.8 MUC2 MUC6
5 spitz nevus 31.6 CDKN2A TP53
6 bile duct cancer 31.6 CCND1 KRT7 TP53
7 gastroesophageal reflux 31.6 CDX2 GAST PTGS2 TP53
8 renal cell carcinoma, papillary, 1 31.5 AMACR KRT7 TP53
9 anus cancer 31.5 CDKN2A CDX2 KRT7
10 mucoepidermoid carcinoma 31.5 KRT7 MUC2 MUC5AC
11 teratoma 31.4 CDX2 KRT7 TP53
12 gallbladder cancer 31.4 CDKN2A MUC2 PTGS2 TP53
13 linitis plastica 31.4 KRT20 KRT7
14 atrophic gastritis 31.3 CDX2 GAST TP53
15 barrett's adenocarcinoma 31.3 CDKN2A PTGS2 TP53
16 oral cancer 31.3 CCND1 CDKN2A PTGS2 TP53
17 ductal carcinoma in situ 31.3 CCND1 PTGS2 TP53
18 small cell carcinoma of the bladder 31.3 KRT20 KRT7
19 neuroendocrine tumor 31.3 GAST KRT20 KRT7
20 cervical cancer 31.3 CCND1 CDKN2A GSTP1 MSR1 PTGS2 TP53
21 vulvar disease 31.2 CDKN2A KRT7 TP53
22 oropharynx cancer 31.2 CCND1 CDKN2A KRT7 TP53
23 intestinal obstruction 31.2 CDX2 KRT20 KRT7
24 superior mesenteric artery syndrome 31.2 CDX2 MUC2 MUC5AC MUC6
25 vulva cancer 31.2 CDKN2A KRT7 TP53
26 colonic disease 31.1 CCND1 CDX2 PTGS2 TP53
27 merkel cell carcinoma 31.1 KRT20 KRT7 TP53
28 squamous cell carcinoma 31.1 CCND1 CDKN2A GSTP1 PTGS2 TP53
29 uterine anomalies 31.1 CCND1 CDKN2A TP53
30 pancreatic cancer 31.1 CCND1 CDKN2A CDX2 GAST MUC2 MUC5AC
31 bladder cancer 31.0 CCND1 CDKN2A GSTP1 KRT20 MUC2 TP53
32 adenoid cystic carcinoma 30.9 CCND1 KRT20 KRT7 TP53
33 pseudomyxoma peritonei 30.8 CDX2 KRT20 KRT7 MUC2 MUC5AC MUC6
34 adamantinoma of long bones 30.8 CCND1 CDKN2A GSTP1 PTGS2 TP53
35 ocular cancer 30.8 CCND1 CDKN2A TP53
36 tubular adenocarcinoma 30.8 CDX2 KRT20 MUC2
37 esophagus adenocarcinoma 30.8 CDX2 PTGS2 TP53
38 polyposis, skin pigmentation, alopecia, and fingernail changes 30.7 CDX2 MUC2 MUC5AC
39 familial adenomatous polyposis 30.7 CCND1 PTGS2 TP53
40 cholangiocarcinoma 30.7 CCND1 CDKN2A CDX2 KRT20 KRT7 MUC2
41 proliferative verrucous leukoplakia 30.6 CDKN2A MCM2
42 gastritis 30.6 CDX2 GAST MUC6 PTGS2 TFF2
43 necrotizing sialometaplasia 30.6 CDKN2A KRT7 TP53
44 small cell carcinoma 30.6 CDKN2A KRT20 KRT7 TP53
45 adenocarcinoma in situ 30.6 CDKN2A CDX2 KRT20 KRT7 MCM2
46 oral leukoplakia 30.6 CCND1 CDKN2A TP53
47 esophageal disease 30.6 CCND1 CDKN2A GAST PTGS2 TP53
48 cystitis cystica 30.4 CDX2 KRT20 KRT7 MUC2 MUC5AC
49 mucinous adenocarcinoma 30.4 CDKN2A CDX2 KRT20 KRT7 MUC2
50 papilloma 30.4 CCND1 CDKN2A KRT20 KRT7 TP53

Graphical network of the top 20 diseases related to Barrett Esophagus:



Diseases related to Barrett Esophagus

Symptoms & Phenotypes for Barrett Esophagus

Human phenotypes related to Barrett Esophagus:

60 33 (show all 11)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 obesity 60 33 hallmark (90%) Very frequent (99-80%) HP:0001513
2 gastroesophageal reflux 60 33 hallmark (90%) Very frequent (99-80%) HP:0002020
3 feeding difficulties in infancy 60 33 hallmark (90%) Very frequent (99-80%) HP:0008872
4 esophageal carcinoma 60 33 hallmark (90%) Very frequent (99-80%) HP:0011459
5 clinodactyly of the 5th toe 60 33 hallmark (90%) Very frequent (99-80%) HP:0001864
6 barrett esophagus 60 33 hallmark (90%) Very frequent (99-80%) HP:0100580
7 esophageal ulceration 33 hallmark (90%) HP:0004791
8 nausea and vomiting 60 33 frequent (33%) Frequent (79-30%) HP:0002017
9 chest pain 60 33 frequent (33%) Frequent (79-30%) HP:0100749
10 cough 60 33 frequent (33%) Frequent (79-30%) HP:0012735
11 lymphadenopathy 60 33 occasional (7.5%) Occasional (29-5%) HP:0002716

Clinical features from OMIM:

614266

MGI Mouse Phenotypes related to Barrett Esophagus:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 10.06 CCND1 CDKN2A CDX2 GAST MCM2 MUC2
2 homeostasis/metabolism MP:0005376 10 AMACR CCND1 CDKN2A CDX2 CTHRC1 GAST
3 endocrine/exocrine gland MP:0005379 9.96 CCND1 CDKN2A CDX2 GAST GDF7 MCM2
4 immune system MP:0005387 9.7 CCND1 CDKN2A GAST MCM2 MSR1 MUC2
5 neoplasm MP:0002006 9.23 CCND1 CDKN2A CDX2 GAST MCM2 MUC2

Drugs & Therapeutics for Barrett Esophagus

FDA approved drugs:

(show top 50) (show all 245)
# Drug Name Active Ingredient(s) 19 Company Approval Date
1
Abraxane 19 50 PACLITAXEL Celgene October 2012
2
Abstral 19 FENTANYL (citrate) ProStrakan January 2011
3
Actiq 19 FENTANYL (citrate) Anesta Corporation November 1998
4
Adcetris 19 50 BRENTUXIMAB VEDOTIN Seattle Genetics August 2011
5
Afinitor 19 50 EVEROLIMUS Novartis March 2009
6
Akynzeo 19 50 NETUPITANT AND PALONOSETRON (hydrochloride) Helsinn October 2014
7
Aloxi 19 50 PALONOSETRON (hydrochloride) MGI Pharma, Helsinn Healthcare August 2003
8
Anexsia 19 ACETAMINOPHEN; HYDROCODONE BITARTRATE Mallinckrodt Group August 1996
9
Anzemet 19 DOLASETRON MESYLATE Hoechst Marion Roussel February 1998
10
Aredia 19 50 PAMIDRONATE DISODIUM Chiron August 1996
11
Arimidex 19 50 ANASTROZOLE AstraZeneca January 1996
12
Aromasin Tablets 19 50 EXEMESTANE Pharmacia & Upjohn October 21. 1999
13
Arranon 19 50 NELARABINE GlaxoSmithKline October 2005
14
Arzerra 19 50 OFATUMUMAB GlaxoSmithKline October 2009
15
Avastin 19 50 BEVACIZUMAB Genentech July 2009
16
Beleodaq 19 50 BELINOSTAT Spectrum Pharmaceuticals July 2014
17
Bexxar 19 50 TOSITUMOMAB; IODINE I 131 TOSITUMOMAB Corixa June 2003
18
Blincyto 19 50 BLINATUMOMAB Amgen December 2014
19
Bosulif 19 50 BOSUTINIB MONOHYDRATE Pfizer September 2012
20
Busulfex 19 50 BUSULFAN Orphan Medical February 1999
21
Campath 19 50 ALEMTUZUMAB Berlex Laboratories May 2001
22
Campostar 19 50 IRINOTECAN HYDROCHLORIDE Pharmacia & Upjohn June 1996
23
CEA-Scan 19 Immunomedics April 1996
24
Cervarix 19 50 Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant GlaxoSmithKline October 2009
25
Clolar 19 50 CLOFARABINE Genzyme December, 2004
26
Cometriq 19 50 CABOZANTINIB S-MALATE Exelixis November 2012
27
Cyramza 19 50 RAMUCIRUMAB Eli Lilly April 2014
28
Degarelix 19 50 degarelix Ferring Pharmaceuticals December of 2008
29
Doxil 19 50 DOXORUBICIN HYDROCHLORIDE Alza June 1999
30
Elitek 19 50 RASBURICASE sanofi-aventis October 2009
31
Ellence 19 50 EPIRUBICIN HYDROCHLORIDE Pharmacia & Upjohn September 1999
32
Elliotts B Solution 19 CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE Orphan Medical October 1996
33
Eloxatin 19 50 OXALIPLATIN Sanofi-aventis August 2002
34
Emend 19 50 APREPITANT FOSAPREPITANT DIMEGLUMINE Merck March 2003
35
Erbitux 19 50 CETUXIMAB Imclone, Bristol-Myers Squibb February 2004
36
Erivedge 19 50 VISMODEGIB Genentech January 2012
37
Erwinaze 19 50 asparaginase Erwinia chrysanthemi Eusa Pharma November of 2011
38
Ethyol 19 AMIFOSTINE Alza December 8, 1995
39
Eulexin 19 FLUTAMIDE Schering-Plough June 1996
40
Evista 19 50 RALOXIFENE HYDROCHLORIDE Eli Lilly September 2007
41
Farydak 19 50 PANOBINOSTAT LACTATE Novartis February 2015
42
Faslodex 19 50 FULVESTRANT AstraZeneca April 2002
43
Femara 19 50 LETROZOLE Novartis January 2001
44
Feridex I.V. 19 FERUMOXIDES Advanced Magnetics February 1996
45
Folotyn 19 50 PRALATREXATE Allos Therapeutics September 2009
46
Fusilev 19 LEVOLEUCOVORIN CALCIUM Spectrum Pharmaceuticals March of 2008
47
Gardasil 19 50 quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine Merck June 2006
48
GastroMARK 19 FERUMOXSIL Advanced Magnetics May 1996
49
Gazyva 19 50 OBINUTUZUMAB Genentech October of 2013
50
Gemzar 19 50 GEMCITABINE HYDROCHLORIDE Eli Lilly May 1996

Drugs for Barrett Esophagus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 177)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2 50-78-2 2244
2
Esomeprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 161796-78-7, 119141-88-7, 161973-10-0 9568614 4594
3
Omeprazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Early Phase 1,Not Applicable 73590-58-6 4594
4
Zinc Approved, Investigational Phase 4,Phase 1 7440-66-6 32051
5
Lansoprazole Approved, Investigational Phase 4,Phase 2 103577-45-3 3883
6
Dexlansoprazole Approved, Investigational Phase 4,Phase 2 138530-94-6, 103577-45-3 9578005
7
Phenylephrine Approved Phase 4 59-42-7 6041
8
Dinoprostone Approved Phase 4 363-24-6 5280360
9
Oxymetazoline Approved, Investigational Phase 4 1491-59-4 4636
10
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
11
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
12
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
13
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
14
Pantoprazole Approved Phase 4,Phase 3 102625-70-7 4679
15
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
16
Polaprezinc Experimental Phase 4 107667-60-7
17
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
18 Liver Extracts Phase 4,Not Applicable
19 Analgesics Phase 4,Phase 3,Phase 2,Not Applicable
20 Proton Pump Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
21 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2
22 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Phase 2
23 Anesthetics Phase 4,Not Applicable,Early Phase 1
24 Anti-Ulcer Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
25 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
26 Antacids Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
27 Antipyretics Phase 4,Phase 3,Phase 2
28 Cyclooxygenase Inhibitors Phase 4,Phase 3,Phase 2
29 Fibrinolytic Agents Phase 4,Phase 3,Phase 2
30 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Not Applicable
31 Antirheumatic Agents Phase 4,Phase 3,Phase 2
32 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Not Applicable
33 Platelet Aggregation Inhibitors Phase 4,Phase 3,Phase 2
34 Trace Elements Phase 4,Phase 1,Early Phase 1
35 Nutrients Phase 4,Phase 1,Early Phase 1
36 Micronutrients Phase 4,Phase 1,Early Phase 1
37 Protective Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
38 Hormones Phase 4,Phase 2,Not Applicable,Early Phase 1
39 Cyclooxygenase 2 Inhibitors Phase 4,Phase 2
40 Neuroprotective Agents Phase 4,Phase 1
41 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Early Phase 1
42 Hormone Antagonists Phase 4,Phase 2,Early Phase 1
43 Omega 3 Fatty Acid Phase 4
44 glucocorticoids Phase 4
45 Antineoplastic Agents, Hormonal Phase 4,Early Phase 1
46 Antiemetics Phase 4
47 Methylprednisolone Acetate Phase 4
48 Autonomic Agents Phase 4
49 Prednisolone acetate Phase 4
50
acetic acid Approved Phase 2, Phase 3,Not Applicable 64-19-7 176

Interventional clinical trials:

(show top 50) (show all 275)
# Name Status NCT ID Phase Drugs
1 Endoesophageal Cryotherapy For Ablating Barrett's Esophagus and Early Stage Esophageal Cancer Unknown status NCT00628784 Phase 4
2 Radiofrequency in the Treatment of Barrett's Oesophagus Unknown status NCT02558504 Phase 4
3 An Open Label pH Comparison of Esomeprazole and Lansoprazole in Barrett's Esophagus Patients Completed NCT00352261 Phase 4 Esomeprazole;Lansoprazole
4 Barrett's Esophagus - 315 - 3 Way Cross-Over Completed NCT00637559 Phase 4 Esomeprazole Magnesium
5 Barrett's Esophagus - 315 - 3 Way Cross Over Completed NCT00637988 Phase 4 Esomeprazole;Aspirin;Rofecoxib
6 Does Intensive Acid Suppression Reduce Esophageal Inflammation and Recurrent Barrett's Esophagus Following Ablation? Completed NCT01093755 Phase 4 dexlansoprazole;Omeprazole
7 Study of CryoSpray Ablation(TM)to Determine Treatment Effect, Depth of Injury, and Side Effects in the Esophagus. Completed NCT00754468 Phase 4
8 Radiofrequency Ablation for the Treatment of Gastric Dysplasia Completed NCT01523912 Phase 4
9 Nissen and Gastroplasty in Gastroesophageal Reflux Disease (GERD) Completed NCT00872755 Phase 4
10 Efficacy of Zinc L-carnosine in Maintaining Remission of Gastroesophageal Reflux Disease Recruiting NCT03467438 Phase 4 Zinc-l-carnosine
11 Modulation of Esophageal Inflammation in Barrett's Esophagus by Omega-3 Fatty Acids Active, not recruiting NCT01733147 Phase 4 Omega-3 free fatty acids;Placebo
12 Barretts oEsophageal Resection With Steroid Therapy Trial Not yet recruiting NCT02004782 Phase 4 Prednisolone;Placebo Oral Tablet
13 Study of CryoSpray Ablation of Low Grade or High Grade Dysplasia Within Barrett's Esophagus Terminated NCT00526786 Phase 4
14 A Trial Comparing Yield of Confocal Endomicroscopy Guided Biopsies Terminated NCT01030263 Phase 4
15 Reduction in Symptomatic Esophageal Stricture Formation Terminated NCT02039115 Phase 4 prednisone;placebo
16 The Clinical Significance of Acid Rebound in Functional Dyspepsia Terminated NCT01373970 Phase 4 Placebo;Pantoprazole + Placebo
17 "Acetic Acid Chromoendoscopy in Barrett's Esophagus Surveillance Unknown status NCT02614703 Phase 2, Phase 3 Chromoendoscopy using Acetic Acid 2.5%
18 A Phase III, Randomized, Study of Aspirin and Esomeprazole Chemoprevention in Barrett's Metaplasia Unknown status NCT00357682 Phase 3 Esomeprazole;Esomeprazole;Aspirin
19 Melatonin Associated to Acid Inhibition for Chemoprevention in Barret Esophagus: a Pilot Study Unknown status NCT01566474 Phase 3 Omeprazole;Melatonin
20 Biomarkers in Phototherapy of Barrett's Esophagus Completed NCT00587600 Phase 2, Phase 3
21 Confocal Endomicroscopy for Barrett's Esophagus Completed NCT00487695 Phase 3
22 An Exploratory Clinical Study of Apatinib for the 2nd Treatment of Esophageal Cancer or Esophageal and Gastric Recruiting NCT03285906 Phase 2, Phase 3 Apatinib
23 Esophageal Metaplasia Using a Novel Antibody: Reversibility by Proton Pump Inhibitor Terminated NCT00161200 Phase 3 Ranitidine & Pantoprazole
24 Safety of Photodynamic Therapy (PDT) in the Ablation of High-grade Dysplasia (HGD) in Barrett's Esophagus (BE) Withdrawn NCT01209013 Phase 3
25 Tethered Capsule Endoscope in Screening Participants for Barrett Esophagus Unknown status NCT00903136 Phase 1, Phase 2
26 Metformin Hydrochloride in Preventing Esophageal Cancer in Patients With Barrett Esophagus Completed NCT01447927 Phase 2 metformin hydrochloride
27 Trial of a Gastrin Receptor Antagonist in Barrett's Esophagus Completed NCT01298999 Phase 2 YF476;Placebo
28 Esomeprazole Magnesium With or Without Aspirin in Preventing Esophageal Cancer in Patients With Barrett Esophagus Completed NCT00474903 Phase 2 acetylsalicylic acid;esomeprazole magnesium
29 Endoscopic Therapy of Early Cancer in Barretts Esophagus Completed NCT00217087 Phase 2
30 Efficacy of CryoBalloon Focal Ablation System on Human Esophageal Barrett's Epithelium Completed NCT02249975 Phase 1, Phase 2
31 Ursodiol in Treating Patients With Barrett Esophagus and Low-Grade Dysplasia Completed NCT01097304 Phase 2 Ursodiol
32 Celecoxib to Prevent Cancer in Patients With Barrett's Esophagus Completed NCT00005878 Phase 2 celecoxib
33 Eflornithine to Prevent Cancer in Patients With Barrett's Esophagus Completed NCT00003076 Phase 2 eflornithine
34 Efficacy and Safety of Sunitinib in Metastatic Gastric Cancer Completed NCT00411151 Phase 2 Sunitinib-Malate
35 Photodynamic Therapy in Treating Patients With Precancerous Esophageal Conditions or Early Stage Esophageal Cancer Completed NCT00281736 Phase 2 HPPH
36 Photodynamic Therapy in Treating Patients With Early Esophageal Cancer Completed NCT00002935 Phase 2 porfimer sodium
37 Radiofrequency Ablation for Gastric Metaplasia and Dysplasia Completed NCT01614418 Phase 1, Phase 2
38 The Impact of Adjuvant Liquid Alginate on Endoscopic Ablation Therapy of Complicated Barrett's Esophagus Recruiting NCT03193216 Phase 2 Alginates
39 Accuracy, Yield and Clinical Impact of a Low-Cost HRME in the Early Diagnosis of Esophageal Adenocarcinoma Recruiting NCT02018367 Phase 2 Proflavine, high resolution imaging
40 A Safety and Efficacy Trial of Circumferential Anal Canal Radiofrequency Ablation for High-Grade Anal Intraepithelial Neoplasia Using the BARRX™ Anorectal Wand Recruiting NCT03302858 Phase 2
41 Radiofrequency Ablation for Barrett Oesophagus With Low Grade Dysplasia Active, not recruiting NCT01360541 Phase 2
42 Aspirin in Preventing Disease Recurrence in Patients With Barrett Esophagus After Successful Elimination by Radiofrequency Ablation Active, not recruiting NCT02521285 Phase 2 Aspirin
43 YF476 in Barrett's Esophagus Enrolling by invitation NCT02597712 Phase 2 YF476;YF476 placebo
44 Detection of Early Esophageal Cancer by NIR-FME. Not yet recruiting NCT03877601 Phase 2 Bevacizumab-IRDye800CW
45 Effect of Dexlansoprazole 60 mg QD and 60 mg BID on Recurrence of Intestinal Metaplasia in Subjects Who Have Achieved Complete Eradication of Barrett's Esophagus With Radiofrequency Ablation Terminated NCT02162758 Phase 2 Dexlansoprazole;Dexlansoprazole Placebo
46 Study of Cryotherapy Treatment of Barrett's Esophagus and Early Esophageal Cancer Terminated NCT00321958 Phase 2
47 Efficacy and Safety of a Sunscreen Against Porfimer Sodium-induced Phototoxicity to Visible Light Withdrawn NCT01256203 Phase 2 Solar Protection Formula SPF® 60
48 The Safety and Tolerability of Secretrol in Patients With Barrett's Esophagus Unknown status NCT01905202 Phase 1 Secretrol
49 Erlotinib in Treating Patients With Barrett Esophagus Unknown status NCT00566800 Phase 1 erlotinib hydrochloride
50 Effect of Zinc on Barrett's Metaplasia Unknown status NCT01984580 Phase 1 zinc gluconate

Search NIH Clinical Center for Barrett Esophagus

Cochrane evidence based reviews: barrett esophagus

Genetic Tests for Barrett Esophagus

Genetic tests related to Barrett Esophagus:

# Genetic test Affiliating Genes
1 Barrett Esophagus 30 ASCC1 CTHRC1 MSR1

Anatomical Context for Barrett Esophagus

MalaCards organs/tissues related to Barrett Esophagus:

42
Lung, Breast, Testes, Endothelial, Prostate, Skin, Bone

Publications for Barrett Esophagus

Articles related to Barrett Esophagus:

(show top 50) (show all 2322)
# Title Authors Year
1
Genetic variants in Barrett's esophagus and esophageal adenocarcinoma: a literature review. ( 30888413 )
2019
2
No Association Between Vitamin D Status and Risk of Barrett's Esophagus or Esophageal Adenocarcinoma-a Mendelian Randomization Study. ( 30716477 )
2019
3
Biomarker identification and trans-regulatory network analyses in esophageal adenocarcinoma and Barrett's esophagus. ( 30670912 )
2019
4
Upregulation of circulating miR130a is correlated with development of Barrett's esophagus and esophageal adenocarcinoma. ( 30588024 )
2019
5
Missed Opportunities for Screening and Surveillance of Barrett's Esophagus in Veterans with Esophageal Adenocarcinoma. ( 30370493 )
2019
6
Increasing prevalence of high-grade dysplasia and adenocarcinoma on index endoscopy in Barrett's esophagus over the past 2 decades: data from a multicenter U.S. consortium. ( 30342028 )
2019
7
Aspirin Plus a High-Dose PPI Prevents Death and Progression in Patients with Barrett Esophagus. ( 30874404 )
2019
8
Possible application of trefoil factor family peptides in gastroesophageal reflux and Barrett's esophagus. ( 30831146 )
2019
9
Screening for esophageal squamous cell carcinoma: insight from experience with Barrett's esophagus. ( 30665537 )
2019
10
Virtual chromoendoscopy by using optical enhancement improves the detection of Barrett's esophagus-associated neoplasia. ( 30291849 )
2019
11
Feasibility of a simplified narrow-band imaging classification system for Barrett's esophagus for novice endoscopists. ( 30603885 )
2019
12
An Interactive Web-based Educational Tool Improves Detection and Delineation of Barrett's Esophagus Related Neoplasia. ( 30610858 )
2019
13
Clinical Outcomes Based on the Timing of Appearance of Visible Lesions in Barrett's Esophagus During Endoscopic Eradication Therapy. ( 30614938 )
2019
14
STRATIFICATION OF THE DYSPLASIA AND NEOPLASIA RISK USING AUTOFLUORESCENCE ENDOSCOPIC SURVEILLANCE OF BARRETT'S ESOPHAGUS. ( 30648638 )
2019
15
Circumferential treatment of long-segment Barrett's esophagus using the next-generation cryoballoon. ( 30658356 )
2019
16
Challenges in Endoscopic Therapy of Dysplastic Barrett's Esophagus. ( 30663018 )
2019
17
Systematic Endoscopy 5 Years After Sleeve Gastrectomy Results in a High Rate of Barrett's Esophagus: Results of a Multicenter Study. ( 30666544 )
2019
18
Correlation of Barrett's Esophagus with Colorectal Polyps in Japanese Patients: A Retrospective Chart Review. ( 30667560 )
2019
19
Methylation Biomarker Panel Performance in EsophaCap Cytology Samples for Diagnosing Barrett's Esophagus: A Prospective Validation Study. ( 30670490 )
2019
20
Comparison of two multiband mucosectomy devices for endoscopic resection of Barrett's esophagus-related neoplasia. ( 30671663 )
2019
21
Omeprazole prevents CDX2 and SOX9 expression by inhibiting hedgehog signaling in Barrett's esophagus cells. ( 30705106 )
2019
22
Liquid Nitrogen Spray Cryotherapy in Treatment of Barrett's Esophagus, where do we stand? A Systematic Review and Meta-Analysis. ( 30715267 )
2019
23
Health-Related Quality of Life Associated with Barrett's Esophagus and Cancer. ( 30719557 )
2019
24
Predictors of Progression in Barrett's Esophagus. ( 30796604 )
2019
25
Barrett's esophagus: What do we need to know? ( 30808502 )
2019
26
Screening for Barrett's Esophagus--Balancing Clinical Value and Cost-effectiveness. ( 30827080 )
2019
27
In-vivo Barrett's esophagus digital pathology stage classification through feature enhancement of confocal laser endomicroscopy. ( 30840732 )
2019
28
Will a PPI and an aspirin keep the doctor away for patients with Barrett's esophagus? ( 30849313 )
2019
29
Over-Utilization of Repeat Upper Endoscopy in Patients with Non-dysplastic Barrett's Esophagus: A Quality Registry Study. ( 30865017 )
2019
30
Economic value of narrow-band imaging versus white light endoscopy for the diagnosis and surveillance of Barrett's esophagus: Cost-consequence model. ( 30865673 )
2019
31
Correction to: NSAID use and somatic exomic mutations in Barrett's esophagus. ( 30867038 )
2019
32
Barrett's Esophagus and Esophageal Carcinoma: Can Biomarkers Guide Clinical Practice? ( 30868278 )
2019
33
Discovery of a novel connecting link between Renin-Angiotensin System and cancer in Barrett's Esophagus by Proteomic screening. ( 30891939 )
2019
34
Challenges to Diagnostic Standardization of Barrett's Esophagus in Asia. ( 30892742 )
2019
35
How I do it: Does this cost-effectiveness analysis convince me about screening for Barrett's esophagus? ( 30902200 )
2019
36
Predictors of dysplastic and neoplastic progression of Barrett’s esophagus ( 30907564 )
2019
37
Optimizing histopathological evaluation of endoscopic mucosal resection specimens of Barrett's esophagus-related neoplasia: a randomized study of 3 specimen handling methods. ( 30910480 )
2019
38
Aberrant p53 Immunostaining in Barrett's Esophagus Predicts Neoplastic Progression: Systematic Review and Meta-Analyses. ( 30911864 )
2019
39
Factors Associated With Recurrence of Barrett's Esophagus After Radiofrequency Ablation. ( 29902646 )
2019
40
Gastroesophageal Reflux Frequency, Severity, Age of Onset, Family History and Acid Suppressive Therapy Predict Barrett Esophagus in a Large Population. ( 29356784 )
2018
41
Microsatellite instability in metaplasia-dysplasia-adenocarcinoma sequence of Barrett esophagus: a retrospective study. ( 29972732 )
2018
42
Barrett Esophagus Length, Nodularity, and Low-grade Dysplasia are Predictive of Progression to Esophageal Adenocarcinoma. ( 29608452 )
2018
43
Carcinoma in situ within an area of Barrett esophagus in a dog with megaesophagus. ( 29952726 )
2018
44
Gastroesophageal reflux disease, Barrett esophagus, and esophageal adenocarcinoma - where do we stand? ( 29972731 )
2018
45
Comparative Assessment of Patient Preferences and Tolerability in Barrett Esophagus Screening: Results From a Randomized Trial. ( 29369237 )
2018
46
Definition of Barrett Esophagus in the United States: Support for Retention of a Requirement for Goblet Cells. ( 29016405 )
2018
47
Evaluation of p53 protein expression in Barrett esophagus. ( 29676351 )
2018
48
Pathology, Chemoprevention, and Preclinical Models for Target Validation in Barrett Esophagus. ( 29959150 )
2018
49
Evaluation of Dysplasia in Barrett Esophagus. ( 29942221 )
2018
50
Efficacy, Durability, and Safety of Complete Endoscopic Mucosal Resection of Barrett Esophagus: A Systematic Review and Meta-Analysis. ( 28134635 )
2018

Variations for Barrett Esophagus

ClinVar genetic disease variations for Barrett Esophagus:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 MSR1 NM_138715.2(MSR1): c.760C> G (p.Leu254Val) single nucleotide variant Pathogenic rs387906645 GRCh37 Chromosome 8, 16021631: 16021631
2 MSR1 NM_138715.2(MSR1): c.760C> G (p.Leu254Val) single nucleotide variant Pathogenic rs387906645 GRCh38 Chromosome 8, 16164122: 16164122
3 CTHRC1 NM_138455.3(CTHRC1): c.131A> C (p.Gln44Pro) single nucleotide variant Pathogenic rs387907029 GRCh37 Chromosome 8, 104384015: 104384015
4 CTHRC1 NM_138455.3(CTHRC1): c.131A> C (p.Gln44Pro) single nucleotide variant Pathogenic rs387907029 GRCh38 Chromosome 8, 103371787: 103371787
5 ASCC1 NM_001198799.2(ASCC1): c.953A> G (p.Asn318Ser) single nucleotide variant Likely benign rs146370051 GRCh37 Chromosome 10, 73892817: 73892817
6 ASCC1 NM_001198799.2(ASCC1): c.953A> G (p.Asn318Ser) single nucleotide variant Likely benign rs146370051 GRCh38 Chromosome 10, 72133059: 72133059

Copy number variations for Barrett Esophagus from CNVD:

7 (show top 50) (show all 157)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 18052 1 143700001 144900000 Amplification BCL9 Esophageal adenocarcinoma
2 19685 1 151000001 155000000 Amplification SKI Esophageal adenocarcinoma
3 21958 1 163432534 163614111 Gain and loss LMX1A Barrett''s syndrome
4 25140 1 184717073 186846060 Gain and loss PLA2G4A Barrett''s syndrome
5 25141 1 184717073 186846060 Gain and loss PTGS2 Barrett''s syndrome
6 29301 1 2300000 5400000 Copy number Esophageal adenocarcinoma
7 33578 1 46425202 46624292 Loss RAD54L Barrett''s syndrome
8 37058 1 84900000 107200000 Loss F3 Esophageal adenocarcinoma
9 39044 10 108165938 109275992 Loss SORCS1 Barrett''s syndrome
10 39081 10 109092539 133471230 Loss BUB3 Barrett''s syndrome
11 39082 10 109092539 133471230 Loss C10orf119 Barrett''s syndrome
12 39083 10 109092539 133471230 Loss NANOS1 Barrett''s syndrome
13 39407 10 114856262 115024106 Loss TCF7L2 Barrett''s syndrome
14 47055 10 89500000 92900000 Copy number Esophageal adenocarcinoma
15 49101 11 102900000 110400000 Copy number Esophageal adenocarcinoma
16 50933 11 120168346 133686875 Loss CHEK1 Barrett''s syndrome
17 50934 11 120168346 133686875 Loss ETS1 Barrett''s syndrome
18 50935 11 120168346 133686875 Loss TIRAP Barrett''s syndrome
19 52231 11 149520 6642613 Loss MUC6 Barrett''s syndrome
20 52232 11 149520 6642613 Loss RHOG Barrett''s syndrome
21 53078 11 2400000 5900000 Copy number CDKN1C Esophageal adenocarcinoma
22 54793 11 474042 626401 Loss HRAS Barrett''s syndrome
23 54794 11 474042 626401 Loss MUPCDH Barrett''s syndrome
24 54795 11 474042 626401 Loss RASSF7 Barrett''s syndrome
25 54796 11 474042 626401 Loss RNH1 Barrett''s syndrome
26 54797 11 474042 626401 Loss SCT Barrett''s syndrome
27 57455 11 63400000 77100000 Gain CCND1 Esophageal adenocarcinoma
28 57457 11 63400000 77100000 Gain EMS1 Esophageal adenocarcinoma
29 57458 11 63400000 77100000 Gain FGF3 Esophageal adenocarcinoma
30 60370 11 8555485 8795697 Loss ST5 Barrett''s syndrome
31 60371 11 8555485 8795697 Loss STK33 Barrett''s syndrome
32 64928 12 133416937 133464204 Copy number CHFR Esophageal adenocarcinoma
33 76216 13 28900000 32200000 Gain BRCA2 Esophageal adenocarcinoma
34 80630 13 95000000 115169878 Gain ABCC4 Esophageal adenocarcinoma
35 80631 13 95000000 115169878 Gain ING1 Esophageal adenocarcinoma
36 83864 14 22278370 23705612 Gain and loss MMP14 Barrett''s syndrome
37 83865 14 22278370 23705612 Gain and loss PCK2 Barrett''s syndrome
38 86372 14 58681498 106175506 Gain and loss FOXN3 Barrett''s syndrome
39 86373 14 58681498 106175506 Gain and loss MAX Barrett''s syndrome
40 86374 14 58681498 106175506 Gain and loss MLH3 Barrett''s syndrome
41 92864 15 44800000 63700000 Loss B2M Esophageal adenocarcinoma
42 95624 15 78300000 102531392 Loss IGF1R Esophageal adenocarcinoma
43 105274 16 77215302 77345302 Loss WWOX Barrett''s syndrome
44 105374 16 7900000 10500000 Copy number Esophageal adenocarcinoma
45 106764 17 1 20774742 Copy number MYBBP1A Esophageal adenocarcinoma
46 106765 17 1 20774742 Copy number TP53 Esophageal adenocarcinoma
47 108120 17 18863807 19044654 Loss GRAP Barrett''s syndrome
48 109777 17 2912016 3092354 Gain and loss Barrett''s syndrome
49 109778 17 2912016 3092354 Gain and loss Esophageal adenocarcinoma
50 110805 17 34303536 34308523 Gain SCYA3 Esophageal adenocarcinoma

Expression for Barrett Esophagus

Search GEO for disease gene expression data for Barrett Esophagus.

Pathways for Barrett Esophagus

GO Terms for Barrett Esophagus

Cellular components related to Barrett Esophagus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 Golgi lumen GO:0005796 8.8 MUC2 MUC5AC MUC6

Biological processes related to Barrett Esophagus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 response to estradiol GO:0032355 9.58 CCND1 GSTP1 PTGS2
2 G1/S transition of mitotic cell cycle GO:0000082 9.54 CCND1 CDKN2A MCM2
3 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.33 MUC2 MUC5AC MUC6
4 replicative senescence GO:0090399 9.32 CDKN2A TP53
5 mitotic G1 DNA damage checkpoint GO:0031571 9.26 CCND1 TP53
6 O-glycan processing GO:0016266 9.13 MUC2 MUC5AC MUC6
7 maintenance of gastrointestinal epithelium GO:0030277 8.92 MUC2 MUC6 TFF2 TFF3

Sources for Barrett Esophagus

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....